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A B S T R A C TObjectives: Few studies have examined hospitalization costs for un-
planned initiation of peritoneal dialysis (PD). We used data from a
health care facility in Mexico to examine first hospitalization costs
associated with the unplanned initiation of PD. Methods: Descriptive
analyses focusing on initial hospitalization costs during the
unplanned initiation of PD were conducted. In addition, multivariate
regression models examined the association of costs with requiring
urgent hemodialysis (HD) at the time of starting PD, and the associa-
tion of driving distance with requiring urgent HD. Results: Of 195
patients hospitalized in 2010 for PD catheter placement, 51 patients
met criteria for unplanned PD initiation and 25 of them required
urgent HD prior to PD initiation. Ninety-two percent of the patients
received 90% or greater government subsidy of hospital costs. Average
inpatient costs for the first hospitalization related to the unplannednt matter Copyright & 2012, International Society
r Inc.
.1016/j.vhri.2012.10.007
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or, Tlalpan. D.F., Me´xico City 14080, Mexico.initiation of PD were 64,174 Mexican Pesos (MXN) (US $4,657). Costs
were 78,683 MXN ($5,710) per patient for those requiring urgent HD
and 50,225 MXN ($3,645) for those who did not, a difference (P o 0.05)
of roughly 28,000 MXN ($2,032), and regression results were similar.
In addition, long driving distance to the institution was significantly
associated with requiring urgent HD. Conclusions: Our findings high-
light potential cost savings to payers for developing better strategies
to manage PD starts in Mexico and should help inform policy
regarding oversight and coverage of low-income patients at risk of
dialysis.
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Copyright & 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic kidney disease (CKD) ranks as the 12th leading cause of
death worldwide and the 11th in Mexico [1,2]. CKD has five defined
stages of irreversible renal function impairment that may ultimately
progress to end-stage renal disease (ESRD) requiring renal replace-
ment therapy (RRT) (i.e., peritoneal dialysis [PD], hemodialysis [HD],
and/or kidney transplantation) for survival [1–4]. Most countries,
including Mexico, have yet to develop and implement prevention,
early detection, and intervention policies for CKD and ESRD, which
may result in an underestimate of the current burden of the disease
[4]. According to the Kidney Early Evaluation Program, CKD is highly
prevalent, with a 22% prevalence rate in Mexico City, but mostly
underdiagnosed and underrecognized even among high-risk indivi-
duals [5]. Different authors talk about the growing incidence and
prevalence of not only CKD but also ESRD in Mexico, estimating in
2008 at least 4.5 million with CKD at any level and 130,000 with ESRD
and RRT requirement [6–8]. Furthermore, in addition to diabetes,
hypertension, and obesity, CKD in Mexico and other countries has
been associated with poverty and low socioeconomic status [7,9,10].Currently, some South American countries have reached uni-
versal access to RRT, while others, including Mexico, have covered
almost two-thirds of the population with social security [2,11]. In
2009, Lo´pez-Cervantes et al. [6] used modeled data and concluded
that there were roughly 129,000 Mexicans with urgent need for
RRT, with only half receiving it by means of social security, leaving
the poor and unemployed without access to RRT [6].
As the use of PD accounts for 60% to 80% of the total population
with RRT in Mexico, understanding PD costs is particularly impor-
tant [6,9,12–15]. Past studies within Mexico have found that the
annual total health care costs per patient of PD were lower than
those for in-center hemodialysis and that PD was cost-effective in
treating patients with ESRD, which may explain why the ratio of in-
center hemodialysis to PD is 24:76 [16–20]. For example, a recent
study in Mexico reported that in 2006 the total treatment-related
costs of PD were $15,724 per patient compared with $24,032
per patient for in-center hemodialysis [16]. In measuring the costs
of PD treatment, hospitalization has been shown to represent a
substantial portion of costs, and this is true in Mexico [21]. In
addition, per patient costs for PD are likely to increase when therefor Pharmacoeconomics and Outcomes Research (ISPOR).
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Fig. 1 – Sample selection and sample sizes for unplanned initiation of peritoneal dialysis (PD). CKD, chronic kidney disease;
HD, hemodialysis.
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initiation, and hospitalizations may be different for the unplanned
initiation of PD in an uninsured population [22]. Furthermore, one of
the reasons hospitalization costs are so important is that RRT
therapy is only available inpatient for the uninsured because they
cannot afford home care, but the government subsidizes inpatient
treatment [6,7,23–25]. Hence, it is useful to focus on understanding
hospitalization costs related to the unplanned initiation of PD in an
uninsured population to inform policy regarding PD treatment. We
are unaware of any published studies regarding the hospitalization
costs of the unplanned initiation of PD for Mexico, or any other
Latin American country. Furthermore, patients who delay care may
require urgent HD prior to being put on PD, and the cost and
outcome implications of those requiring urgent HD versus those
who do not have not been studied in a Latin American population.
This study presents new information about hospitalization
costs associated with unplanned PD initiation in an uninsured
population in 2010 from a high specialty health care facility from
a payer perspective. Furthermore, the study compares costs for
patients who required urgent HD at the time of initiating PD
versus those who did not and examines the association of
distance from the clinic on the need for urgent HD.Methods
Data
The project utilized highly detailed retrospective data based on
linked medical and financial claims records from the National
Institute of Cardiology Ignacio Chavez in Mexico from January to
December 2010. This hospital and clinic in Mexico serves patients
who do not have social security in Mexico. Every patient receives
a socioeconomic survey that takes into account the address andemployment of the patient, and that information is used to
determine the level of subsidy.
The data allowed selection of patients experiencing unplanned
initiation of PD along with detailed information regarding inpatient
costs. The patients in the data were first identified on the basis of
surgical records at the hospital indicating PD catheter placement
for the first time within the time frame of January 1, 2010, to
December 31, 2010. Within that group, incident unplanned patients
were selected on the basis of information from the hospital’s
ambulatory clinic. In particular, patients with any PD-related visit
scheduled during the 3 months prior to the surgery were excluded.
Furthermore, the clinical notes for the patients in the medical
records were checked and patients with a primary reason for
surgery denoted as starting PD were included. Finally, one patient
was excluded for having a history of HD treatment before switch-
ing over to PD treatment. From the selected population of
unplanned initiation of PD, medical records were used to further
identify patients who required urgent HD during the initial hospi-
talization for PD catheter placement (see Fig. 1).
For each patient, detailed patient demographic and clinical
records as well as inpatient costs were collected from financial
claims and medical records. We also observed the level of
government subsidy issued for each patient. Distance from the
hospital was also estimated on the basis of knowledge of the
hometown of the patient in the medical record. Costs were
available at several levels of granularity down to the item code;
however, it was not possible to associate dates for costs other
than the admission and discharge date of the hospitalization.
Note that in examining the costs of PD bags, we discovered
inconsistencies between the financial records and the lists of
supplies given to patients. PD bags have fewer controls than
other supplies, and often the information for the PD bags that
were given to poorer patients was not passed along to financial
claims. Consequently, for costs associated with PD bags, which
are part of the pharmacy supplies department, we subtracted the
Table 1 – Descriptive characteristics of patients with unplanned PD initiation.
All patients Required HD Did not require HD
Sample size 51 25 26
Demographics
Age (y), mean  SD 49.35  18.52 47.99  18.59 50.65  18.73
Males (%) 54.90 52.00 57.69
SES (%)
Govt. subsidy Z 90% 92.16 100.00 84.62
Govt. subsidy ¼ 70% 5.88 0.00 11.53
No govt. subsidy 1.96 0.00 3.85
Distance
Traveling distance to hospital (km), mean  SD 61.44  103.63 77.94  113.56 45.58  92.55
Percent with distance4 39.5 km 23.53 40.00 7.69
Other risk factors (%)
Diabetes 41.18 44.00 38.46
Hypertension 41.18 32.00 50.00
Cardiovascular† 21.57 16.00 26.92
Autoimmunityz 5.88 4.00 7.69
Kidney allograft failure 7.84 4.00 11.54
MDRD§, mean  SD 6.03  4.29 4.59  3.42 7.41  4.64
Govt., government; HD, hemodialysis; PD, peritoneal dialysis; SES, socioeconomic status.
* Indicates differences across required HD that were statistically significant at the 5% level (t test for continuous variables and Fisher’s exact
test for proportions).
† Cardiovascular is any combination of congestive heart failure, coronary artery disease, or cardiovascular disease.
z Autoimmunity is either microscopic polyangitis or systemic lupus erythematosus.
§ MDRD stands for modification of diet in renal disease and is based on the four-variable equation and measured in terms of ml/minute/1.73 m2.
Lower values indicate worse functioning.
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the medical records using a cost of 25 Mexican Pesos (MXN)
($1.81) for each bag. 25 MXN was equivalent to the charges for the
same type of bags seen in the claims data. All other cost data
came straight from the financial records and were consistent
with the other available data. In all the analyses, the data used
had been delinked and deidentified, and the project was found to
be exempt by official institutional review board review.Statistical Analyses
Detailed descriptive analyses of available patient demographics,
including distance patients traveled, as well as a variety of detailed
clinical characteristics were conducted for all the included patients
and across patients who required urgent HD versus those who did
not during the initial visit. For the same sets of patients, costs
associated with the first hospitalization were examined. Further-
more, costs were grouped and described at the hospital department
level (e.g., Procedures, Imaging, Lab Tests, and Hospital Beds). All
costs were reported in 2010 MXN and converted to US dollars for
display here on the basis of a currency exchange rate published at
the central bank of Mexico Web site (http://www.banxico.org.mx/
indexEn.html) on May 16, 2012, of 13.7799 MXN for each US dollar.
Standard t tests for continuous variables and Fisher’s exact tests
for frequency variables were conducted across those with and
without urgent HD prior to PD initiation to establish statistical
significance at the 5% level. In addition, we conducted multivariate
modeling of costs to examine the impact of requiring urgent HD
controlling for available risk measures in the data: age, gender,
government subsidy status, residual renal function, and presence
of comorbidities. Specifically, following recommendations in Man-
ning and Mullahy [26], we determined that a generalized linear
model with a log link would be most consistent and ran a modified
park test that suggested the gamma distribution. Predicted costs
with the indicator for having urgent HD set to 1 for everyone minus
the predicted costs with everyone coded as 0 for urgent HD werethen used to estimate the marginal impact of urgent HD on costs.
Finally, logistic regression was used to examine the relationship
between requiring urgent HD and living in the upper quartile of
distance, again controlling for available risk measures. All analyses
used STATA SE version 11 (College Station, TX).Results
There were 195 prevalent patients for PD-related surgery and 77
incident patients. Of the 77 incident patients, 51 unplanned starts
of dialysis were identified and of these 51 patients, 25 required
urgent HD during their visit for the initial PD surgery (see Fig. 1).
Table 1 contains descriptive characteristics of the patient
population. Although few variables were statistically significant
across the groups, in the HD group the estimated glomerular
filtration rate using the modification of diet in renal disease
formula was lower and the proportion of patients driving further
than 39.5 km was higher.
The average total cost of the first hospitalization for an
unplanned start of PD was 64,174 MXN (US $4,657), with most of
the costs categorized as hospital bed rates and procedures (Table 2).
Costs of the first hospitalization were 78,683 MXN ($5,710) per
patient for those requiring urgent HD prior to PD initiation and
50,225 MXN ($3,645) for those not requiring HD prior to PD
initiation. Consistent with the descriptive results, the regression
results (see Table 3) indicated a significant coefficient for urgent HD
(Po 0.01) and the marginal predicted impact of urgent HD was
21,955 MXN ($1,593). In the regression results, the hypertension
coefficient was not significant at the 5% level, but it was negative,
which was unexpected. There are no direct clinical reasons that
would explain why patients with hypertension would have lower
costs versus those without hypertension. The population without
hypertension in this study, however, did appear to be different. We
found that patients without hypertension had much lower residual
renal function measured with the modification of diet in renal
Table 2 – Per patient costs of first hospitalization by department (2010 MXN).
Costs of first hospitalization Full sample of unplanned
initiation of PD (n ¼ 51)
Required urgent HD during
PD initiation (n ¼ 25)
Did not require
urgent HD (n ¼ 26)
Department
Blood bank and blood products 424.08 (o1%) 816.00 (1%) 46.96 (o1%)
Pharmacy supplies 3027.14 (5%) 3632.26 (5%) 2445.30 (5%)
Drugs 3,086.65 (5%) 3,233.44 (4%) 2,945.50 (6%)
Hospital bed rates 28,301.88 (44%) 34,267.68 (44%) 22,565.54 (45%)
Imaging 4,588.12 (7%) 5,840.32 (7%) 3,384.08 (7%)
Laboratory tests 7,068.71 (11%) 8,215.56 (10%) 5,965.96 (12%)
Operating room material 1,006.32 (2%) 1,637.91 (2%) 399.01 (1%)
Procedures 16,318.98 (25%) 21,039.36 (27%) 11,780.15 (23%)
Professional service fees 352.92 (o1%) 0.00 (0%) 692.27 (1%)
Total 64,174.79 78,682.81† 50,224.77†
HD, hemodialysis; PD, peritoneal dialysis.
* The costs presented are mean values. To obtain the costs in US dollars, an exchange rate of 13.7799 Mexican pesos per US dollar should be
used (see text for details).
† Denotes statistically significant differences at the 5% level across groups; note here only the differences in total costs were tested across
groups by using a t test for continuous variables.
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larger percentage of them who required urgent HD.
Table 4 contains results from the logistic regression on
requiring urgent HD. We found that patient age, gender, and
most of the comorbidities (kidney allograft failure the exception)
were not significantly related. However, an indicator for being in
the upper quartile of distance from the hospital (living4 39.5 km
away) had a statistically significant odds ratio of greater than 20
for requiring urgent HD.Discussion
To our knowledge, this is the first study in Mexico to examine
hospitalization costs for unplanned PD initiation [6]. The averageTable 3 – General linear model regression of costs for first
hospitalization on urgent HD and other risk factors.
GLM
Regression
DV: Total cost of first
hospitalization
P
Urgent HD 0.344 0.007




Had cardiovascular 0.065 0.810
Had diabetes 0.020 0.915
Had hypertension 0.393 0.086






AIC, akaike information criterion; DV, dependent variable; GLM,
generalized linear model; HD, hemodialysis.
* Regression was a gamma GLMwith a log link using robust errors.
Predicted costs with urgent HD set to 1 for everyone were 75,347
MXN, and were 53,392 MXN with urgent HD set to 0.
† MDRD stands for modification of diet in renal disease and is
based on the four-variable equation and measured in terms of
ml/minute/1.73 m2. Lower values indicate worse functioning.age and rate of diabetes in our population were consistent with
those found in larger registries of dialysis patients in Mexico,
particularly if you look at numbers for those without social
security [27]. Our population had low socioeconomic levels, with
92.16% eligible for a 90% or greater government subsidy for
hospital costs. The analyses revealed substantial costs associated
with the first hospitalization of unplanned starts of PD in Mexico.
Furthermore, patients who required urgent HD at the time of
initiating unplanned PD treatment were associated with an
increase in the cost of first hospitalization of 21,955 MXN
($1,593) controlling for available patient characteristics. We also
found that living more than 39.5 km (the upper quartile of
distance in the sample) from the hospital was significantly
related to requiring HD. To add some context, a previous study
estimated that the total societal perspective treatment costs per
patient for PD were $15,724 in 2006 [16]. The costs of the firstTable 4 – Logistic regression on patients requiring urgent
HD during PD initiation.
Logistic regression DV: Required
urgent HD
P






Had cardiovascular 0.350 0.243
Had diabetes 2.526 0.308
Had hypertension 0.782 0.764
Had autoimmune 1.161 0.925
Had kidney allograft failure 0.099 0.046
Psuedo R2 ¼ 0.2738
DV, dependent variable; HD, hemodialysis; PD, peritoneal dialysis.
* Note that subsidy of 90% or more could not be used in the
logistic regression because all patients with urgent HD had 90%
or more subsidy. Coefficients reflect odds ratios. The results are
for a logistic model with robust standard errors.
† MDRD stands for modification of diet in renal disease and is
based on the four-variable equation and measured in terms of
ml/minute/1.73 m2. Lower values indicate worse functioning.
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were over 25% of that number, and substantially more for those
requiring urgent HD [16]. Overall, the results support that delays
and/or poor awareness of the need for care for patients can raise
costs for institutions.
PD is recognized as an important treatment for patients with
chronic kidney conditions in Latin America and especially Mexico
[9,12]. In Mexico, however, there currently is no structured policy
for early detection. Adding to the concern is that RRT is unba-
lanced between people with and without health coverage. Access
to treatment is restricted for patients without coverage, and it
is reflected by dialysis rates that are almost one third less than for
people with coverage. In addition, there are few facilities with the
capability to offer dialysis treatment to this group, and services
are limited. Meanwhile, patients have to pay at least part of the
treatment costs and this precludes some patients from receiving
adequate treatment. Furthermore, most hospitals are located in
big cities and can be far from where patients at risk are living. The
distance means more costs, which many cannot afford. Although
beyond the scope of our study, there can by significant costs not
only for the patients but for relatives as well [12].
The results help quantify the potential benefit of improved
screening, particularly if screening can reduce the need for
urgent HD at the time of PD initiation. Public screening in Mexico
has yet to develop; however, a pilot for the Kidney Early Evalua-
tion Program has been applied in Mexico City and Jalisco. This
program aims to detect renal disease in high-risk populations
such as those with diabetes and hypertension. According to the
results from the screening, the prevalence of CKD was 22% in
Mexico City and 33% in Jalisco, which was similar to the Kidney
Early Evaluation Program report in the United States (prevalence
26%). An important finding was that most of the participants
were unaware of the CKD diagnosis. The authors conclude that
CKD is highly prevalent, underdiagnosed, and underrecognized in
high-risk individuals in Mexico [5]. Another Mexican survey in
an urban Mexican population showed that the percentage of the
population in each stage of renal function as suggested by the
Kidney Disease Outcomes Quality Initiative guidelines was simi-
lar between Mexican and US populations [10]. Given the pre-
valence levels, there is room for better programs to help improve
patient outcomes and save resources.
With respect to the health system, about 50% of the popula-
tion is covered by three social security institutions: Instituto
Mexicano del Seguro Social, Instituto de Seguridad y Servicios
Social para los Trabajadores del Estado, and the Army. The
remaining half of the population is left to take care of itself.
In the past 5 years, a new voluntary popular insurance adminis-
tered by the Health Ministry saw some take up in low-income
populations, where there are currently 10 million poor people in
Mexico. Only patients within the social security system have
universal coverage including RRT and only one institution, the
Instituto Mexicano del Seguro Social, takes care of about 80% of
the current patients with ESRD on treatment [9]. Hence, overall,
50% of the Mexican population receives treatment similar to
those given in this institute. Because it is highly unlikely that
Mexico will be able to afford the expense of maintaining a large
dialysis population, as in the developed world, it is only through
prevention that Mexico can adequately face this devastating
disease [12]. Policymakers have not yet assigned the time and
resources needed to prepare the Mexican health care system for
the rapidly growing burden of ESRD [9].
Much remains to be learned regarding this patient population
and these treatments. In addition to the concerns raised above, a
major issue is that patients with PD are rarely able to restart their
working life. Future research into treatments will help in under-
standing the decision between continuous ambulatory peritoneal
dialysis and automated peritoneal dialysis (APD). For example,APD can free up therapy during the day so that patients can begin
to work again. A promising area is to look at getting APD for
younger patients to reincorporate them into working life. The
institute that provided the data for this project has begun its own
formal PD program. Evaluation of that program and similar ones
in Latin America would provide further important information
for shaping policy toward these patients.
Limitations
The results are from a retrospective data analysis of a single year
in a single institution in Mexico. Hence, our sample size was
limited. In addition, the findings are most likely to apply to public
health institutions that provide in-hospital acute RRT to unin-
sured ESRD patients with low socioeconomic status, but caution
should be taken in generalizing the findings to other settings. In
addition, there was inherently no information on care received or
the clinical characteristics across time in the patients prior to
starting PD. The multivariate analyses, because of the limited
retrospective data, may suffer from omitted variable bias and low
statistical power.Conclusions
The results help quantify the magnitude of costs of unplanned
PD starts for low-income patients in Mexico, particularly for
those patients who experience delayed care to the point where
they require urgent HD. The findings assist in understanding the
potential gains from improved oversight of PD. They suggest
particularly high benefits for strategies that could prevent the
need for urgent HD at the time PD is initiated. Also, patients in
relatively remote areas may be at a higher risk of requiring urgent
HD at the time of hospitalization for unplanned initiation of PD.
Overall, the costs highlight the importance of promoting patient
awareness of and encouraging PD initiation as soon as it is
clinically warranted. This should help inform policy for develop-
ing a well-structured PD program to enhance oversight and
coverage of low-income patients at risk of dialysis in Mexico.
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